Trials / Terminated
TerminatedNCT02875093
Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML
Phase 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Polaris Group · Industry
- Sex
- All
- Age
- 17 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of safety and tolerability of drug combination and determine time on treatment, Overall survival (OS) and response rate with patient disease burden, and type of disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADI-PEG 20 | Investigational Medicine |
| DRUG | Cytarabine | low-dose cytarabine 20 mg BID twice daily for 10 days, every 28 days |
Timeline
- Start date
- 2017-01-20
- Primary completion
- 2019-07-10
- Completion
- 2019-07-10
- First posted
- 2016-08-23
- Last updated
- 2020-03-05
Locations
3 sites across 1 country: Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02875093. Inclusion in this directory is not an endorsement.